The Genome:
We, with our colleagues at Tufts University School of Veterinary Medicine, the University of Virginia, and the MRC Cambridge, have recently sequenced the genome of C. hominis, the primary cause of human cryptosporidiosis. This sequence and the nearly 4,000 C. hominis genes now deposited in our database as well as several additional public gene and protein databases, now forms the basis of future analysis into the biology and pathogenesis of this important parasite, and into the development of new vaccine and chemotherapeutic targets. This project is funded by grant number NIH RO1 AI46418.

Functional Genomics:
Taking advantage of the availability of the sequence of C. hominis, we, again with our colleagues at Tufts University School of Veterinary Medicine, have embarked on a study of the gene expression profiles of this important pathogen during its development and differentiation within the mammalian host. Parallel studies are examining the host cell response after Cryptosporidium infection. Again, we anticipate that these studies will lead to new strategies for intervention in this important disease. This project is funded by grant number NIH R01 AI55347.

Vaccine Development:
The genome sequence of C. hominis revealed dozens of potential vaccine targets. Working with colleagues at the University of Virginia, we are expressing, purifying and testing these antigens for their abilities to block infection of mammalian cells or induce a strong protective or therapeutic immune response. This project is part of the Mid Atlantic Research Center of Excellence for the Study of Potential Agents of Biological Terrorism and Emerging Infectious Diseases, grant number NIH U34 AI57168.